Shopping Cart 0
Cart Subtotal
USD 0

Aslan Pharmaceuticals Pte Ltd (6497) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company's pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan's ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore City, Singapore.

Aslan Pharmaceuticals Pte Ltd (6497)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Aslan Pharma Raises USD23 Million in Venture Financing 12

Aslan Pharma Raises Additional USD9 Million in Venture Financing 14

Aslan Pharma Raises USD34 Million in Series C Financing 16

Aslan Pharma Raises USD 22 Million In Series B Financing 18

Partnerships 20

Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20

Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21

ASLAN Pharma Enters into Agreement with ACT Genomics 22

Licensing Agreements 23

Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23

ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24

ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25

Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28

Equity Offering 29

Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29

Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31

Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32

Aslan Pharma Raises USD33.2 Million in IPO 33

Aslan Pharmaceuticals Pte Ltd-Key Competitors 34

Aslan Pharmaceuticals Pte Ltd-Key Employees 35

Aslan Pharmaceuticals Pte Ltd-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 06, 2018: Aslan pharmaceuticals reports second quarter 2018 financial results and provides corporate update 37

Corporate Communications 38

Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 38

Product News 39

08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 39

08/10/2018: ASLAN Pharmaceuticals completes recruitment for global phase 2 study for Varlitinib in first line gastric cancer 40

05/17/2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO 41

01/31/2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 42

01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 43

01/18/2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China 44

Product Approvals 45

Aug 20, 2018: ASLAN Pharmaceuticals granted Orphan Drug Designationby the FDA for ASLAN003 for the treatment of acute myeloid leukaemia 45

Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 46

Clinical Trials 47

Oct 09, 2018: Aslan Pharmaceuticals to present poster on Varlitinib at European Society for Medical Oncology congress 47

Sep 17, 2018: ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China 48

Jul 03, 2018: Aslan Pharmaceuticals Submits Clinical Trial Authorisation Application For First In Man Studies For ASLAN004 49

Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR 50

Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China 51

Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 52

Nov 13, 2017: Aslan Pharmaceuticals Receives IND Approval In Singapore To Initiate Phase 2 Study Of ASLAN003 In Acute Myeloid Leukaemia 53

Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 54

Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 55

Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 56

Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 57

Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 58

Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 59

Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 60

May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 61

Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 62

Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 63

Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aslan Pharma Raises USD23 Million in Venture Financing 12

Aslan Pharma Raises Additional USD9 Million in Venture Financing 14

Aslan Pharma Raises USD34 Million in Series C Financing 16

Aslan Pharma Raises USD 22 Million In Series B Financing 18

Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20

Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21

ASLAN Pharma Enters into Agreement with ACT Genomics 22

Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23

ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24

ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25

Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28

Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29

Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31

Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32

Aslan Pharma Raises USD33.2 Million in IPO 33

Aslan Pharmaceuticals Pte Ltd, Key Competitors 34

Aslan Pharmaceuticals Pte Ltd, Key Employees 35

Aslan Pharmaceuticals Pte Ltd, Other Locations 36

Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aslan Pharmaceuticals Pte Ltd , Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aslan Pharmaceuticals Pte Ltd (Aslan), a subsidiary of Aslan Pharmaceuticals Ltd, is a biotechnology company that offers immuno-oncology agents and targeted therapies. The company's pipeline products comprise varlitinib, ASLAN002, ASLAN003 and ASLAN004. Its ASLAN002 is a small molecule inhibitor of RON and cMET receptor tyrosine kinases for the treatment of gastric and breast cancer. Aslan's ASLAN003 is a small molecule inhibitor of dihydroorotate dehydrogenase inhibitor to treat tumors; and ASLAN004 is a full human monoclonal antibody that reduces exacerbation in moderate or severe asthma and improves the functioning of lungs. It operates in Singapore, Taiwan, China and Australia. Aslan is headquartered in Singapore City, Singapore.

Aslan Pharmaceuticals Pte Ltd (6497)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Aslan Pharma Raises USD23 Million in Venture Financing 12

Aslan Pharma Raises Additional USD9 Million in Venture Financing 14

Aslan Pharma Raises USD34 Million in Series C Financing 16

Aslan Pharma Raises USD 22 Million In Series B Financing 18

Partnerships 20

Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20

Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21

ASLAN Pharma Enters into Agreement with ACT Genomics 22

Licensing Agreements 23

Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23

ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24

ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25

Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28

Equity Offering 29

Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29

Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31

Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32

Aslan Pharma Raises USD33.2 Million in IPO 33

Aslan Pharmaceuticals Pte Ltd-Key Competitors 34

Aslan Pharmaceuticals Pte Ltd-Key Employees 35

Aslan Pharmaceuticals Pte Ltd-Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Recent Developments 37

Financial Announcements 37

Aug 06, 2018: Aslan pharmaceuticals reports second quarter 2018 financial results and provides corporate update 37

Corporate Communications 38

Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 38

Product News 39

08/31/2017: ASLAN Pharmaceuticals Announces First Patient Enrolled in a Global Phase 2/3 Study for Varlitinib in Gastric Cancer 39

08/10/2018: ASLAN Pharmaceuticals completes recruitment for global phase 2 study for Varlitinib in first line gastric cancer 40

05/17/2018: ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO 41

01/31/2018: ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018 42

01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 43

01/18/2018: ASLAN Pharmaceuticals Appoints Stephen Doyle as Head of China 44

Product Approvals 45

Aug 20, 2018: ASLAN Pharmaceuticals granted Orphan Drug Designationby the FDA for ASLAN003 for the treatment of acute myeloid leukaemia 45

Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 46

Clinical Trials 47

Oct 09, 2018: Aslan Pharmaceuticals to present poster on Varlitinib at European Society for Medical Oncology congress 47

Sep 17, 2018: ASLAN Pharmaceuticals Provides Update on Timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China 48

Jul 03, 2018: Aslan Pharmaceuticals Submits Clinical Trial Authorisation Application For First In Man Studies For ASLAN004 49

Apr 17, 2018: ASLAN Pharmaceuticals Announces Presentation of New Pre-Clinical Data on Varlitinib in Hepatocellular Carcinoma at AACR 50

Jan 08, 2018: ASLAN Pharmaceuticals announces shortened timeline to commercialisation for varlitinib in China 51

Jan 02, 2018: Aslan Pharmaceuticals Abstract On Varlitinib Wins Best Poster At ESMO Asia 2017 52

Nov 13, 2017: Aslan Pharmaceuticals Receives IND Approval In Singapore To Initiate Phase 2 Study Of ASLAN003 In Acute Myeloid Leukaemia 53

Nov 08, 2017: ASLAN Pharmaceuticals Announces Poster Presentation at ESMO Asia Congress 2017 54

Sep 07, 2017: Aslan Pharmaceuticals Announces Initiation Of First Clinical Study In Hepatocellular Carcinoma For Varlitinib 55

Jun 29, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Global Pivotal Treetopp Study For Varlitinib In Biliary Tract Cancer 56

Jun 12, 2017: Aslan Pharmaceuticals Announces MTD For Varlitinib In Combination With Chemotherapies Commonly Used In First Line Gastric Cancer 57

Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 58

Jun 02, 2017: Aslan Pharmaceuticals Announces Publication of New Varlitinib Data in Metastatic Solid Tumours at ASCO 59

Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer 60

May 18, 2017: New Data On Varlitinib Published At 2017 Annual Meeting Of American Society Of Cancer Oncology 61

Apr 25, 2017: ASLAN Pharmaceuticals Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 62

Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 63

Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65


List Of Figure

List of Figures

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aslan Pharma Raises USD23 Million in Venture Financing 12

Aslan Pharma Raises Additional USD9 Million in Venture Financing 14

Aslan Pharma Raises USD34 Million in Series C Financing 16

Aslan Pharma Raises USD 22 Million In Series B Financing 18

Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 20

Aslan Pharma Enters into MoU with National Cancer Centre Singapore 21

ASLAN Pharma Enters into Agreement with ACT Genomics 22

Aslan Pharma Enters into Licensing Agreement with Array BioPharma 23

ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 24

ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 25

Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 26

Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 27

Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 28

Aslan Pharma Raises USD42.2 Million in Public Offering of Shares 29

Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31

Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32

Aslan Pharma Raises USD33.2 Million in IPO 33

Aslan Pharmaceuticals Pte Ltd, Key Competitors 34

Aslan Pharmaceuticals Pte Ltd, Key Employees 35

Aslan Pharmaceuticals Pte Ltd, Other Locations 36

Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aslan Pharmaceuticals Pte Ltd , Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.